lorazepam has been researched along with aripiprazole in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chakraborty, N; Johnston, T | 1 |
| Fricchione, GL; Huffman, JC | 1 |
| Aderhold, V; Haasen, C; Lambert, M; Reimer, J | 1 |
| Caroff, SN; Hammerman, S; Lam, C | 1 |
| Auby, P; Manos, G; Marcus, RN; McQuade, RD; Oren, DA; Stock, E; Zimbroff, DL | 1 |
| Citrome, LL; Crandall, DT; Currier, GW; Manos, G; McQuade, R; Oren, D; Pikalov, AA; Zimbroff, DL | 1 |
| Calabrese, JR; Carlson, BX; Carson, WH; Eudicone, JM; Keck, PE; Marcus, RN; McIntyre, RS; McQuade, RD; Sanchez, R | 1 |
| Chriki, LS; Dunn, RT; Filkowski, MM; Ghaemi, SN; Stan, VA | 1 |
| Kovalick, LJ; McQuade, RD; Naringrekar, VH; Ni, N; Pikalov, AA | 1 |
| Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL | 1 |
| Bria, P; Janiri, L; Mazza, M; Pecora, RD; Squillacioti, MR | 1 |
| Cummings, TS; Noordsy, DL | 1 |
| Carter, WG; Lauterbach, EC; Norris, BK; Shillcutt, SD | 1 |
| Greenway, LL; Kuppuswamy, PS; Lauterbach, EC | 1 |
| Jean-Baptiste, M; Mukai, Y; Two, A | 1 |
| Adams, CE; Jones, H; Powney, MJ | 1 |
| Golla, H; Perrar, KM; Voltz, R | 1 |
| Fraile, S; García, B; Hidalgo, FJ; Lopez, E | 1 |
| Amano, N; Hanihara, T; Takahashi, T; Takahashi, Y; Washizuka, S; Yasaki, T | 1 |
| Csomor, PA; Geyer, MA; Huber, T; Preller, KH; Studerus, E; Vollenweider, FX | 1 |
| Kar, SK; Srivastava, A | 1 |
| Garel, N; Joober, R | 1 |
3 review(s) available for lorazepam and aripiprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazepam; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Sleep; Thiazoles | 2012 |
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Delirium; Evidence-Based Medicine; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Olanzapine; Palliative Care; Piperazines; Quinolones; Risk Factors | 2013 |
5 trial(s) available for lorazepam and aripiprazole
| Article | Year |
|---|---|
Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Headache; Humans; Injections, Intramuscular; Lorazepam; Male; Nausea; Patient Dropouts; Piperazines; Psychomotor Agitation; Quinolones; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Vomiting | 2007 |
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; GABA Modulators; Humans; Lorazepam; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Remission Induction; Secondary Prevention; Severity of Illness Index; Surveys and Questionnaires | 2007 |
A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Lorazepam; Male; Middle Aged; Nausea; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2008 |
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Dopamine Antagonists; Double-Blind Method; Female; Hospitalization; Humans; Lorazepam; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Triglycerides; United States; Young Adult | 2008 |
Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Headache; Humans; Lorazepam; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Young Adult | 2008 |
17 other study(ies) available for lorazepam and aripiprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Aripiprazole and neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Lorazepam; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Schizophrenia | 2004 |
Catatonia and psychosis in a patient with AIDS: treatment with lorazepam and aripiprazole.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Anxiety Agents; Anti-HIV Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Lorazepam; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Manifestation of multiple sclerosis with paranoid-hallucinatory psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diet; Epilepsy, Generalized; Female; Hallucinations; Humans; Hypnotics and Sedatives; Hypothyroidism; Lorazepam; Magnetic Resonance Imaging; Multiple Sclerosis; Paranoid Disorders; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Neuroleptic malignant syndrome and aripiprazole.
Topics: Adolescent; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder; Female; Humans; Intellectual Disability; Lorazepam; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; United States | 2006 |
Intramuscular aripiprazole in the control of agitation.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Arousal; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2007 |
Short-term physical compatibility of intramuscular aripiprazole with intramuscular lorazepam.
Topics: Aripiprazole; Drug Combinations; Drug Incompatibility; Humans; Injections, Intramuscular; Lorazepam; Piperazines; Quinolones; Time Factors | 2008 |
Treatment of catatonic schizophrenia with lorazepam and aripiprazole.
Topics: Adult; Aripiprazole; Female; Humans; Hypnotics and Sedatives; Lorazepam; Piperazines; Quinolones; Schizophrenia, Catatonic | 2009 |
Catatonia and CPK elevation in neurosyphilis: role of plural pharmacodynamic mechanisms.
Topics: Adult; Aripiprazole; Catatonia; Creatine Kinase; Dose-Response Relationship, Drug; Doxycycline; Humans; Lorazepam; Male; Neurosyphilis; Piperazines; Quinolones; Temazepam; Valproic Acid | 2009 |
Differential pharmacological responses of catatonia-like signs in frontotemporal dementia.
Topics: Aged; Amantadine; Antipsychotic Agents; Aripiprazole; Benzothiazoles; Catatonia; Citalopram; Clinical Trials as Topic; Dibenzothiazepines; Donepezil; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Frontotemporal Dementia; Humans; Hypnotics and Sedatives; Indans; Lorazepam; Memantine; Middle Aged; Nootropic Agents; Piperazines; Piperidines; Pramipexole; Quetiapine Fumarate; Quinolones; Selective Serotonin Reuptake Inhibitors | 2010 |
Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; Combined Modality Therapy; Dopamine Agents; Female; Fluvoxamine; GABA Modulators; Humans; Lorazepam; Memantine; Neurosurgical Procedures; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2011 |
[Possible malignant neuroleptic syndrome associated with aripiprazole and imipramine and treated with bromocriptine].
Topics: Antipsychotic Agents; Aripiprazole; Bromocriptine; Combined Modality Therapy; Drug Therapy, Combination; Emergencies; Frontotemporal Dementia; Humans; Imipramine; Lorazepam; Male; Mental Disorders; Middle Aged; Neuroleptic Malignant Syndrome; Oxygen Inhalation Therapy; Piperazines; Quinolones; Respiration, Artificial; Respiratory Insufficiency | 2013 |
Cavum septum pellucidum and cavum vergae with late-onset catatonia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Brain; Catatonia; Cysteine; Electroconvulsive Therapy; Female; Humans; Hypnotics and Sedatives; Lorazepam; Magnetic Resonance Imaging; Organotechnetium Compounds; Piperazines; Quinolones; Radiopharmaceuticals; Septum Pellucidum; Somatoform Disorders; Tomography, Emission-Computed, Single-Photon | 2013 |
Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.
Topics: Acoustic Stimulation; Amisulpride; Antipsychotic Agents; Aripiprazole; Auditory Perception; Benzhydryl Compounds; Brain; Double-Blind Method; Electroencephalography; Electromyography; Humans; Lorazepam; Male; Modafinil; Piperazines; Prepulse Inhibition; Psychometrics; Psychotropic Drugs; Quinolones; Risperidone; Sensory Gating; Sulpiride; Valproic Acid; Young Adult | 2014 |
Attributions to new onset catatonic symptoms, late in the course of chronic schizophrenia.
Topics: Amlodipine; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; GABA Modulators; Humans; Hydrochlorothiazide; Lorazepam; Male; Middle Aged; Schizophrenia; Telmisartan; Time | 2017 |
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiency
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Delusions; Dystonia; Female; Hallucinations; Humans; Hypnotics and Sedatives; Intellectual Disability; Lorazepam; Loxapine; Olanzapine; Paranoid Disorders; Psychotic Disorders; Quetiapine Fumarate; Tourette Syndrome | 2019 |